Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perfect , perfect , perfect !!! Be debt free by DEC 9th , have mega millions in CASH left offer ( about $ 75 million !! ) , then sell out for a honkin big premium by the end of 2008
( their stated goal at yesterdays conference call ) .
Throw in any positive clinical trials on Parkinsons & Alzheimers and look out above .
Did I say perfect ...yup , I did , P..E..R..F..E..C..T !!!!!
Was at work so I missed the shock wave .
Renee
The news yesterday was excellent in EVERY way . We should not underestimate the sheer power of ~ 12 million short positions in CEGE . I have no doubts the amoral MM's are keeping the PPS as low as they can so that short positions can cover for as low as possible . The best counter-measure is for retail investors to buy the cheaper shares in competition with the shorters which should eventually compel the MM's to raise the PPS .
It is not unreasonable to think that Lazard could present a buyout offer rather quickly for several dollars per share which would really pressure the shorters to buy-in at any cost .
If ever there was a buy and hold then the very undervalued CEGE is that stock .
The PPS in the meantime is quite irrelevant to the imminent buyout price for CEGE .
Renee
Five Star analyst ranking for CEGE . link :
http://finance.yahoo.com/q/sa?s=cege
Parkinsons and Alzheimer trials ongoing . Any positive results from those trials will add a tremendous premium to CEGE in a buyout .
With $151 million in cash , cash equivalents , and short term investments , CEGE is worth much more than .33 cents in a buyout , so the trading PPS does not accurately reflect the company's worth .
This lass will wait for the premium buyout price which is targetted to happen before the end of 2008 !
Renee
CEGE investor conference call on Nov. 12th . EOM
From the C.C. :
1. Clinical Trials are still going on for other pipelines .
2. Sale of CEGE will happen " expeditiously " . The Company has recently engaged Lazard to assist the Company in the evaluation of strategic alternatives , including merger with or acquisition by another company , further restructuring, allocation of resources toward other biopharmaceutical product areas , and/or sale of the Company's assets.
3. A re-assessment of GVAX is in progress .
4. Ceregene involvement is definitely a lifeline .
5. Looking to maximize value to stockholders .
6. Estimated CASH by end of 2008 should be $121 million .
7. Company has until July 2009 to regain Nasdaq compliance .
IMO , CEGE is quite undervalued even under .50 cents .
Renee
CEGE : " The company ended the quarter with approximately $151 million in cash , cash equivalents and short-term investments . "
On October 15th there is a purported 12.7 million short position in CEGE . With todays 10Q conference call possibly the shorts are catching up to cover .
There's ~ 86 million O/S per last 10Q so IMO the short position is disproportionately large .
Posted by: acgood Date: Monday, October 27, 2008 2:41:56 PM
In reply to: None Post # of 557
short interest down somewhat:
9/30 : 15.1 million shares
10/15 : 12.7 million
CEGE : .40 on 185,000 volume
CEGE : From the 2nd quarter 10Q assets were $295 million and CEGE's PPS was ~ $4.00-ish , so take note of today's 3rd quarter 10Q for comparisons .
IMO CEGE's PPS is undervalued at .35 cents .
Renee
Cell Genesys Earnings Conference Call (Q3 2008)
Scheduled to start Thu, Nov 6, 2008, 4:30 pm Eastern
http://biz.yahoo.com/cc/0/98810.html
After the event has finished, the audio will be available
from this page until Sat, Nov 7, 2009
About Cell Genesys (NasdaqGM:CEGE) Other Calls
Cell Genesys, Inc., a biotechnology company, engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies. The company’s GVAX cancer Immunotherapies comprise Prostate Cancer, a phase III product for the treatment of prostate cancer; Pancreatic Cancer, a phase II product for pancreatic cancer; and Leukemia, a phase II product for the treatment of acute and chronic myelogenous leukemia, and myelodysplastic syndrome. Its Oncolytic Virus Therapy includes CG0070, a phase I product for the treatment of recurrent bladder cancer. Cell Genesys has alliance with Novartis AG for the development and commercialization of oncolytic virus therapies; research and development collaboration with Medarex, Inc.; and development and commercialization collaboration of GVAX immunotherapy with Takeda Pharmaceutical Company Limited for prostate cancer. The company was founded in 1988 and is headquartered in South San Francisco, California.
Not in just yet , Blockman , but possibly tomorrow .
And then I will bring you much lady luck , hahaha .
:)
Renee
The pleasure is mine , J. , and you're welcome , Lifegear .
I guess I had better dabble in TWKGQ tomorrow . Just been a spectator up til now .
Renee
# 100 just for you :)
Renee
Cheeses , CEGE .43 ( + 39 % ) .....nice . EOM
.41 ( + 32 % ) and rising on merit . EOM .
.35 ( + 14 % ) , steady rise every day . EOM .
And if CEGE's 10Q is satisfactory then the PPS theoretically should return to dollar land . The conference call tomorrow after-hours will clarify important issues that caused the dramatic price drop from $3.00-ish in late August .
Renee
Cell Genesys to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Wednesday November 5, 8:30 am ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE - News) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update on Wednesday, November 12, 2008, at 2:25 p.m. ET at the Rodman & Renshaw 10th Annual Healthcare Conference being held in New York City, New York.
A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.
Cell Genesys, Inc. (Nasdaq:CEGE - News) is a biotechnology company headquartered in South San Francisco. For additional information, please visit the Company's website at www.cellgenesys.com.
President-Elect Obama defines inspiration and humility . A most rendering acceptance speech .
I saw many tears of joy in the attendees tonight .
The world is grateful !
Renee
Congratulations , U.S.A. , on electing a President whom the whole world approves !
Bless the United States of America !
Renee
Agreed in point . However , I have been watching international news stations that strongly favor an Obama Presidency to positively impact the stock markets over a prolonged period , in contrast to a short-lived spurt just because the Elections are over .
Renee
Since our planet is a global village I anticipate much stronger stock markets around the world with an Obama Presidency .
Renee ( a Canadian perspective )
.35 A/H ( + .10 today ) . EOM .
Going higher in A/H . EOM .
.30 , finally . EOM
You betcha ( LOL ) ...~ $100 million CASH in CEGE's coffers .
CEGE's 10Q will be out before the conference call on thursday , after-hours .
If the 10Q is strong then the shorts will have no choice but to buy higher ....hopefully MUCH higher .
CEGE should have run like a gazelle this morning , but I think the forthcoming 10Q and of course the rotten-to-the-core MM's are holding the stock in this range .
I bought more this morning . Holding heavy .
Renee
.31 pre-market , and rising . EOM .
And insiders & institutions were buying heavy over the last 2 weeks . Always follow THEIR lead , cuzz they always know more than all retail holders combined .
To a great day .
Renee
Yup ...terrific for CEGE . Lots of liquid cash in their coffers too ....mega millions .
Renee
Fabulous news !! Copied below :
Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Tuesday November 4, 9:00 am ET
SAN DIEGO, Nov. 4 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that the University of California, San Diego (UCSD) has received a $5.4 million grant from the National Institute of Aging at the National Institutes of Health (NIH) to support a Phase 2 clinical study of Ceregene's CERE-110, a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. A Phase 1 study of CERE-110 indicated that a single administration of the therapy was well tolerated, though the study was too small to make a definitive statement about treatment efficacy.
Ceregene anticipates initiating the Phase 2 study, which is expected to enroll 50 patients with mild to moderate Alzheimer's disease at multiple clinical trial sites in the U.S. early next year. The study will be double-blinded and will evaluate the treatment arm versus an appropriate control arm with respect to safety measures and cognitive function and quality of life at two years.
"We are pleased to be involved in evaluating CERE-110 which we believe may be a promising therapy for Alzheimer's disease," stated Paul Aisen, M.D., principal investigator of the planned Phase 2 trial and director of the Alzheimer's Disease Cooperative Study at University of California, San Diego, a preeminent research consortium for testing new treatments for Alzheimer's disease. "Over five million people in the U.S. are currently living with Alzheimer's disease -- a disease which is devastating to patients and their families -- and we are in need of more effective treatment options for these patients."
"The safety profile that we have observed from CERE-110 in the Phase 1 study is very encouraging, and we are delighted that this NIH grant will enable us to further evaluate this product candidate. We are especially grateful for this funding given that it was based on peer review, and we look forward to using it to advance this product. The development of CERE-110 was led by Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer and is a continuation of the pioneering work of Mark Tuszynski, M.D., Ph.D., Ceregene's co-founder and a professor of Neurosciences at UCSD," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Similar to the other therapies in our pipeline which target Parkinson's disease, ocular disorders and ALS (Lou Gehrig's disease), CERE-110 may have the ability to not only treat the symptoms of Alzheimer's disease but to protect dying neurons and potentially result in the slowing of disease progression."
About CERE-110
CERE-110 is composed of an adeno-associated viral (AAV) vector carrying the gene for NGF, a naturally occurring protein that maintains survival of nerve cells in the brain. CERE-110 is surgically injected into the Nucleus Basalis of Meynert (NBM), a brain region where cholinergic cell degeneration occurs in Alzheimer's disease. The cholinergic system is important in memory and cognitive function, and a restoration in the function of this system may improve memory in individuals with Alzheimer's disease. Delivery of NGF using an AAV vector should have the potential to induce sustained expression of NGF, resulting in long-lasting restoration of the function.
The Phase 1 study was conducted at Rush University Medical Center, Chicago and UCSD. The open-label study involved 10 subjects with mild-to-moderate Alzheimer's disease. The administration of CERE-110 was generally safe and well tolerated. The 10 participants underwent cognitive testing, measures of activities of daily living, MRI scans and PET (positron emission tomography) scans. Increases in brain metabolism were observed in several cortical regions at six months and 12 months (p < 0.05) in four subjects as compared to other severity-matched individuals with Alzheimer's disease suggesting a potential reversal of patterns typically observed in Alzheimer's disease.
About Alzheimer's Disease
Alzheimer's disease is a progressive disorder of the brain that gradually affects one's memory and ability to learn, reason, communicate and carry out daily activities. There are now more than five million people in the United States living with Alzheimer's disease, and there is currently no cure.
About Ceregene
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE - News) as well as Hamilton BioVentures and California Technology Partners.
Yup ...double nice . EOM .
Excellent article , Acgood . CEGE is a funder of Ceregene's
Parkinson's trials .
Nice !!
Renee
I was sooooooooo WRONG on this stock . If anyone bought from any influences of my posts I sincerely apologize . I really did believe that LTDI was credible .
I have very DARK , DARK thoughts towards Orlando and Carolina , and I truly hope they are standing in line behind O.J. on J.Day .
One day they will account for their criminal actions .
Charlene the STUPID Tuna ....c'est moi .
Renee
Terrific webcast !! It has been my learned experience over the last 8+ years of investing that a profitable , reporting company whereby insiders own more than 25 % of the outstanding shares is a solid , GROWTH investment .
By my calculations the CHDO insiders own 58 % of the outstanding shares which is the strongest validation that THEY believe they own a GROWTH investment . *** Insiders' DD of any stock is much more indepth than all retail holders combined so overwhelming insider vested interest is an extremely strong validation and to me is the BEST forward guidance possible .
It is also a terrific validation from the lender to have an asset / accounts receivable line of credit that does not encumber the equity , which is typically toxic for OTCBB and OTC stocks . That means that CHDO has a perfect credit standing for paying on time . A BIGGIE !!!!!
I owned another stock a few years ago that had approximately the same level of institutional and insider ownership and that stock went from $1.05 to over $12.85 in the span of a few months . The point being that GROWTH investments are the SAFEST investments in the entire stock market .
Great 10Q . Great webcast .
Renee
Profitability is the best forward guidance ANY company can give . I think many Nasdaq , NYSE , and Amex stocks would be envious to just break even , let alone be profitable .
I look forward to hearing the conference call when I get home from work .
Continued GROWTH through 2009 will tremendously impact the share price per quarter .
Renee
Nov 6th for the Conference Call :
Cell Genesys to Webcast Third Quarter 2008 Conference Call
Cell Genesys, Inc. (Nasdaq:CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company’s third quarter financial results that will be broadcast live over the internet on Thursday, November 6, 2008, at 1:30 p.m. PT/ 4:30 p.m. ET.
The webcast will be available on the investor relations section of the company’s website, www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.
Cell Genesys, Inc. (Nasdaq:CEGE) is a biotechnology company headquartered in South San Francisco. For additional information, please visit the Company's website at www.cellgenesys.com.
Au contraire , Playerguy . Thanks to the magnanimous SEC naked short selling has been legal for many years so that the Market Makers can make a liquid market in illiquid / low volume stocks and / or an orderly market in liquid / high volume stocks . *** excepting the recent SEC rules .
It is the Failure To Deliver the naked short shares that is illegal ....yet the SEC has never prosecuted or sanctioned even one offender ...NOT ONE .
Renee
Very strong 10Q . I gladly paid .02 today to add to my previous position .
Excellent , task oriented I-HUB board as well .
Renee